Log In
BCIQ
Print this Print this
 

INO-3112

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionCombination of VGX-3100, a DNA-based therapeutic vaccine targeting the E6 and E7 proteins of HPV 16 and 18, and INO-9012, an immune activator of IL-12
Molecular Target Human papillomavirus (HPV) antigens ; Interleukin-12 (IL-12)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$27.5M

$700.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/10/2015

Undisclosed

$27.5M

$700.0M

Get a free BioCentury trial today